61 results about "Liver Dysfunctions" patented technology

The invention relates to a glycyrrhizic acid derivative, preparation thereof and use thereof. The derivative has high water solubility and high storage stability and is suitable to be used in medicaments and health-care products for treating or preventing hepatitis, liver cirrhosis, hemorrhagic fever of liver damage and liver dysfunction syndrome, allergic purpura, psoriasis vulgaris, eczematousdermatitis and the like.

The inventors have discovered that food and pharmaceutical compositions containing (−)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for preventing and treating diverse conditions, e.g., stomach ulcers, portal hypertension, liver dysfunction, diabetes and obesity. The invention provides methods for delaying gastric emptying and increasing receptive relaxation in individuals. The invention also provides methods of preventing or treating disorders or conditions related to aberrant gastric emptying and receptive relaxation.

The invention discloses a Chinese medicinal stagnancy-removing and stagnation-eliminating soup for treating liver depression and qi stagnation type indigestion. The soup is prepared specific to liver depression and qi stagnation type indigestion which is mostly caused by liver dysfunction, disturbance in ascending and descending of spleen, stomach and qi mechanisms and weakening of the function of transformation and transport due to internal emotional injury, stomach impairment caused by diet, spleen impairment caused by overstrain and the like from Chinese medicinal herbs with liver soothing, melancholy dispelling, qi regulating and distension relieving effects, such as corydalis tuber, indian bread, rhizoma atractylodis macrocephalae, liquoric root, salvia miltiorrhiza, curcuma root, Chinese angelica root, astragalus, codonopsis pilosula, Chinese yam, Chinese date, dried old orange peel, clove, round cardamom and amomum fruit through scientific combination. As proved by clinical trial, the soup has the total efficiency up to 96.0 percent, the treating effect remarkably better than that of a contrast group and no untoward reaction, and is worthy of clinical popularization and application.

The purpose of the present invention is to provide a Hugan products and their preparation methods, as described including chrysanthemum, dandelion, wolfberry, cassia seed, Angelica dahurica and schisandrin, carried out by a special combination of natural herbs, effective prevention, and treatment to improve liver dysfunction, such as the role of disease, and its preparation method is simple, stable process conditions suitable for the scale of chemical production.

Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.

The invention discloses a Chinese medicinal external application medicament for treating thyroid nodules. The thyroid nodules belong to the domain of Chinese medical 'warts', and are formed by dysfunction of spleen in transportation and retaining of internal phlegm in the Adam's apple due to depression and liver dysfunction. All grass or root of common calanthe, capparis acutifolia, securidaca inappendiculata, homlockleaved moonwort, trifoliate orange, spiral shell, bryozoatum and souliea vaginata are ground into powder, a proper amount of ginger juice is added to the powder to form paste, and the paste is externally applied to an affected part; through clinical test in the hospital, the total effectiveness is 93.3 percent and is obviously superior to that of a control group; and the medicament is worthy of clinical popularization and application.

The invention relates to porridge for treating chloasma, in particular to traditional Chinese medicine bovine liver porridge for treating chloasma, which takes vegetal Chinese herbal medicines as raw materials. The porridge comprises the following raw materials in parts by weight: 400-600 parts of bovine liver, 50-150 parts of rice, 25-35 parts of loofah, 6 parts of peach kernel, 6 parts of safflower, 8 parts of feverfew, 8 parts of white silkworm, 8 parts of white peony root, 10 parts of poria extract, 10 parts of capillary wormwood herb and 3 parts of raw liquorice. The porridge provided by the invention has the efficacies of dispersing stagnated liver qi, nourishing yin and invigorating the kidney, regulating qi and blood, activating blood circulation to dissipate blood stasis, clearing away heat and toxic materials, relaxing the bowels, removing freckles and acnes, moisturizing the skin and the like; and the porridge is mainly used for treating chloasma caused by disorder of qi and blood on face resulting from liver dysfunction, stagnation of liver qi, liver fire caused by long-time stagnation, impairment to yin and blood, blood stasis, deficiency of spleen qi, dysfunction of the spleen in transportation and failure in essence metaplasia.

The present invention provides a metabolism regulating and liver protecting nutritional supplement, a preparation method and applications thereof. The metabolism regulating and liver protecting nutritional supplement contains 10 to 50 parts of alpha-ketoglutarate bis-arginine and is effervescent tablet or buccal tablet. On the other hand, the present invention provides a preparation method for the metabolism regulating and liver protecting nutritional supplement. The method comprises four steps of dispensation, pulverization, pelletization, and obtain the finished product. The present invention also provides applications of the metabolism regulating and liver protecting nutritional supplement on alleviating hangover to protect liver and daily care. The metabolism regulating and liver protecting nutritional supplement can regulate the liver dysfunction, and can directly and quickly provide nutrient and plenty of cell energy for liver cells to absorb and utilize, thereby maintaining the normal functions and health of the liver

The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs.

The present invention provides a highly safe composition which is effective for protecting liver functions and preventing liver dysfunctions in the case where liver dysfunctions rise by various causes. The present inventors found that oxidized coenzyme Q is effective for protecting liver functions in the absence of selenium and that reduced coenzyme Q has a higher efficacy for protecting liver functions. The composition containing, as the main components, oxidized coenzyme Q and less than 0.01 percent by weight of selenium, or reduced coenzyme Q can be used to protect liver functions. The present invention can provide a highly safe composition which is highly effective for maintaining health.

Provided is a non-human animal that is highly practical as a hyperuricenia model, the non-human animal being the following:(a) a non-human animal obtained by producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction; and subsequently administering a purine base-containing substance to the primary chimeric non-human animal, or(b) a non-human animal obtained by producing a serially transplanted chimeric non-human animal via two steps, a first step being a step of producing a primary chimeric non-human animal by transplantation of human hepatocytes to an immunodeficient non-human animal with liver dysfunction, a second step being a step of transplanting the human hepatocytes grown in the body of the primary chimeric non-human animal to an immunodeficient non-human animal with liver dysfunction, the second step being performed one or more times; and subsequently administering a purine base-containing substance to the serially transplanted chimeric non-human animal.

The invention provides a peptide and a composition thereof for improving liver dysfunction, wherein the peptide and the composition thereof can take a preventive effect or a curative effect on liver dysfunction and can be used for preparing drugs and food. The liver dysfunction particularly refers to a non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatosis hepatitis (NASH) or liver dysfunction caused by hepatitis viruses, alcohol, stress, drug or immunologic abnormality.

The invention relates to usage of Roxadustat in preparation of drugs for treating sepsis. In order to solve the problem of lack of therapeutic drugs for treating sepsis and organ dysfunction, such asheart dysfunction, liver heart dysfunction and the like, the invention provides novel usage of Roxadustat in preparation of drugs for treating sepsis as well as organ dysfunction, such as heart dysfunction, liver heart dysfunction and the like, thereby effectively reducing fatality rate of sepsis as well as treating organ dysfunction, such as cardiovascular dysfunction, liver dysfunction and the like, caused by sepsis.

The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.

Glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, such as septic shock. The present invention further relates to variant GPI-PLD polypeptides modified at the phosphorylation site at amino acids 689-692 of the mature human wild-type protein.

The invention belongs to the technical field of medicine and health food, and particularly relates to application of an ampelopsis grossedentata water extract in preparation of a preparation for improving liver injury. The ampelopsis grossedentata water extract disclosed by the invention can be used for effectively regulating intestinal flora disorder, improving intestinal barrier function damage and reducing inflammatory response of liver injury by regulating diversity of intestinal flora of mice, obviously increasing SOD (superoxide dismutase) content of serum of the mice and improving oxidation resistance of liver cells. The invention has positive application value for treating and preventing acute and chronic liver injury by regulating intestinal microecological disorder by utilizing the ampelopsis grossedentata water extract, improving liver dysfunction of patients and delaying the development of liver fibrosis of the patients. The ampelopsis grossedentata water extract and the composition thereof can be used for preventing and treating diseases for improving intestinal microecological disorder caused by various reasons.

This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and / or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.

The invention relates to a Chinese medicine composition for liver dysfunction, which is compounded by yam flour and pinenut kernels. The invention also relates to a preparation method of the yam flour and a preparation method of the Chinese medicine composition. The medicine has obvious curative effect on the symptoms of limosis nausea, deficient belly flatulence and poor appetite caused by the liver dysfunction and has the advantages of scientific and reasonable recipe, good curative effect, simple and convenient material taking, convenient and easy implementation, economy, practicability and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to application of glucosamine in preparation of a medicine for treating non-alcoholic fatty liver disease. Experiments prove that the glucosamine with the daily dose of 300-600 mg / kg can improve insulin resistance, glycolipid metabolism disorder and liver lipid accumulation of mice with the non-alcoholicfatty liver disease, improve liver dysfunction, enhance oxidation resistance, and reduce body inflammation and serum endotoxin level. Therefore, the glucosamine has a certain treatment effect on thenon-alcoholic fatty liver disease.

The invention discloses a making method of a healthy tea-flower cake. The healthy tea-flower cake is prepared from raw materials in parts by weight as follows: 48-50 parts of cake flour, 23-25 parts of medium strength flour, 0.4-0.6 parts of yeast, 8-10 parts of green tea juice, 4-6 parts of Gentiana flowers, 2-4 parts of Hibiscus sabdariffa, 3-5 parts of common peonies, 2-4 parts of fleshfingered citron flowers, 0.5-0.7 parts of white granulated sugar, 4-6 parts of purple sweet potatoes, 3-5 parts of potatoes, 6-8 parts of carrots and 1.3-1.5 parts of wort. The tea juice component contained in the cake crust and flower pulp components contained in the cake stuffing are blended mutually, the greasy performance as well as high sucrose and high fat in the traditional tea-flower cake is eliminated, a flavor component is produced after fermentation, and absorption and use are promoted; actions of the tea juice and the flower pulp supplement each other, and the health care function is improved, so that the tea-flower cake has the health effects of maintaining beauty, keeping young, astringing the lung to stop cough, reducing blood pressure, regulating qi, promoting appetite, nursing qi and blood, enriching yin and nourishing kidney, and can effectively prevent and treat sore throat, indigestion, chapped skin and liver dysfunction.

The invention discloses a Chinese medicinal combination for treating fatty liver due to dampness and heat accumulation. The pathogenesis of fatty liver can be summarized in liver dysfunction, liver congestion, dysfunction of the spleen in transport, no removal of damp evil, internal production of phlegm, loss of kidney qi and phlegm stagnation. The fatty liver due to dampness and heat accumulation is caused by dampness and heat accumulation, loss of smoothly moving state of the liver and failure in catharsis. Thus, traditional Chinese medicines having the effects of clearing heat, promoting diuresis, eliminating phlegm, removing stasis and promoting blood circulation to remove blood stasis, such as Indian nightshade root, buttonbush root, flabelate maiden-hair herb, mallotus root, simon plum root leaf, laxflower pottsia root, asiatic cudweed, Indian melothria root, rosa taiwanensis, snakeroot, snake bramble seed and humifuse euphorbia herb are decocted with water into a decoction. Proven by the clinical test, the total effective rate is up to 97.8 percent and is remarkably higher than that (86.7 percent) of a control group, being 86.7 percent. Moreover, patients in a treatment group do not have remarkable adverse reaction during treatment.

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.

This is a glycyrrhizic single-sylvite film coating and its preparing method, which belongs to medicine technique field. Its characteristic is: it takes surbased glycyrrhizic single-sylvite plate, whose diameter is 0.8- 1.2cm as bullet base, and the bullet surface has a 0.3-0.9mm depth dressing material film coating, and the dressing material is damp-proofing. The manufacturing technique of glycyrrhizic single-sylvite film coating contains plate preparation and film coating preparation. This film coating is small, low cost, it has good damp-proofing, strong stability, it increases disintegration and dissolving rate of bullet, heightens biology availability and clinical curative effect. This glycyrrhizic single-sylvite film coating is available for auxiliary therapy in acute and chronic hepatic diseases and liver dysfunction patients, at the same time it relives the use limitation in diabetes patients.

The invention discloses a medical complex containing silybin di-partial succinate, a preparation method and an application thereof. The silybin di-partial succinate and phospholipid are dissolved in an organic solvent based on a certain ratio, drying and concentration are carried out after heating and refluxing, and the product is obtained. The complex not only enhances the solubility of silybin but also enhances the lipid solubility and obviously improves the problem of low bioavailability. The complex has the effect of protecting a liver and can be used in the therapy of acute and chronic hepatitis, fatty liver and other liver dysfunctions.

The present invention provides use of a composition comprising ferrous amino acid chelate for the manufacture of a medicament for treatment of liver dysfunction, wherein the medicament comprises an effective amount of the ferrous amino acid chelate composition and a pharmaceutically acceptable carrier. The present invention proves that the serum biochemistry values related to the liver function can be reduced by administering the composition comprising ferrous amino acid chelate. For animals whose liver functions cannot be improved by long-term administration of S-adenosylmethionine, their liver functions can be effectively improved by administration of the composition comprising ferrous amino acid chelate of the present invention instead. Furthermore, the composition comprising ferrous amino acid chelate can improve the functions of an aged liver.

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

Most chronic liver diseases are notoriously asymptomatic, until cirrhosis with clinical decompensation occurs. The use of early diagnosis strategies is vital to maintain patients in a symptom-free state and to delay decompensation, and thus improve the outcome. Albumin (HAS) undergoes several post-translational modifications in hepatocytes but clinical relevance of some of these modifications has been recently investigated in advanced liver diseases. Now, the inventors demonstrate that the binding capacities of some ligands, measured by inductively coupled plasma mass spectrometry (ICP-MS), are significantly different between cirrhotic patients and patients with no liver dysfunctions. The decreased binding capacities in cirrhotic patients were paralleled by the presence of significantly higher HSA isoforms Animal experimentations were also conducted to explore the precocity of HSA modifications in the course of chronic liver dysfunction. This allow the inventors to assume that the most important modifications of albumin structure due to liver dysfunction could be revealed by measuring the unbound fraction of specific ligands spiked in serum.